Stay ahead of open-angle glaucoma

Article

Researchers reported that the preclinical detectable phase for OAG is about 10 years.

Swedish researchers have been looking for the earliest signs of open-angle glaucoma (OAG) that would prove beneficial to patients.

They reported that the preclinical detectable phase for OAG, defined as the mean time from which glaucoma can be detected by screening to its clinical diagnosis, is about 10 years, according to Johan Aspberg, MD, lead study author from the Department of Clinical Sciences in Malmö, Ophthalmology, Lund University, Jan Malmö, Sweden.1

Such screening is important, he explained, because a 50% reduction of glaucoma-related blindness was achieved in a population that was screened for OAG.

Aspberg and colleagues conducted population-based screening for OAG in 32,918 patients from 1992 to 1997. The medical records were reviewed retrospectively to determine the prevalence of new OAG cases at screening, the incidence of new cases after screening, and the clinical incidence of new glaucoma cases expected to be detected without screening, he described. A total of 2,029 patients (66.6% women) were included in the current study, and the investigators analyzed the data from March 2020 to October 2021.

They calculated the preclinical detectable phase for OAG using 2 methods: by dividing the prevalence of the screening-detected glaucoma with the clinical incidence and using a Markov chain Monte Carlo (MCMC) model simulation that simultaneously derived both the length of the mean preclinical detectable phase and the screening sensitivity.

A total of 1,420 patients (mean age at screening, 67.4 years) were screened.

Based on the 2 calculations, the investigators reported that the mean lengths of the preclinical detectable phase for OAG of the entire study population were 10.7 years (95% confidence interval, 8.7-13.0) by the prevalence/incidence method and 10.1 years (95% credible interval, 8.9-11.2) by the MCMC method.

The mean preclinical detectable phases for the 2 methods were similar “A mean preclinical detectable phase of 10 years found in the current study allows for screening with reasonably long intervals, e.g., 5 years,” the investigators commented.

Reference
1. Aspberg J, Heijl A, Bengtsson B. Estimating the length of the preclinical detectable phase for open-angle glaucoma. JAMA Ophthalmol. Published online November 23, 2022. doi:10.1001/jamaophthalmol.2022.5056

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Matt Jones, OD; Matt Burns, OD; and Joe Sugg, OD; detailed what optometrists can expect to change when HB 1353's regulations are enacted later this year.
Dana Shannon, OD, FAAO, shares pearls on spotting red flags in need of referral and enhancing patient care with follow-up compliance.
Dana Shannon, OD, FAAO, detailed a lecture she gave at the NOA Midwestern Symposium earlier this month.
CRU 2025 provided the latest insights regarding glaucoma, dry eye disease, retina, myopia, neurotrophic keratitis, and keratoconus.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, gave 2 presentations alongside other ODs and MDs at CRU 2025.
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
© 2025 MJH Life Sciences

All rights reserved.